Schwarz Builds its Business in the Public Eye
Schwarz Pharma is a publicly-held mid-sized pharmaceutical company in Germany with a business model that emphasizes its marketing and sales strengths in Germany. It does little R&D of its own, preferring to license in products from outside. To compete against others seeking to license in products, it offers its strengths in the German market. Its recent deal with Novartis AG to co-market the hypertension drug valsartan is an example of this strategy.
You may also be interested in...
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.